Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 24

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 8
Chunk 24
---
 received from sale of Series B Preferred Stock, net of issuance costs 
     418,316  
     -  
     - 
  
    Proceeds received from sale of Series C Preferred Stock, net of issuance costs 
     803,561  
     -  
     - 
  
    Proceeds from Series A preferred warrant exercises 
     938,800  
     -  
     - 
  
    Net cash provided by financing activities 
     13,727,634  
     -  
     571,678 

    Net increase (decrease) in cash and cash equivalents 
     1,449,065  
     (637,400) 
     (5,218,309)

    Cash, restricted cash and cash equivalents at beginning of period 
     1,877,995  
     1,601,255  
     6,819,564 

    Cash, restricted cash and cash equivalents at end of period 
    $3,327,060  
    $963,855  
    $1,601,255 

    SUPPLEMENTAL CASH FLOW INFORMATION: 

    Cash and cash equivalents 
    $3,252,304  
    $884,099  
    $1,521,499 
  
    Restricted cash 
     74,756  
     79,756  
     79,756 
  
    Cash, restricted cash and cash equivalents 
    $3,327,060  
    $963,855  
    $1,601,255 

    NON-CASH FINANCING ACTIVITIES: 

    Issuance of common shares to Keystone Capital LLC for equity line of credit 
    $500,000  
     -  
    $- 
  
    Issuance of common shares to Arena Capital Partners for equity line of credit 
    $500,000  
    $-  
    $- 
  
    Conversion of Series A and Series B preferred stock to common stock 
    $9,037,773  
    $-  
    $- 
  
    Stock subscription receivables 
    $803,044  
    $-  
    $- 
  
    Increase in deferred offering costs and accounts payable 
    $112,232  
    $-  
    $- 
  
    Exercise of warrants for Series